Slow-Release Theophylline Rationale and Basis for Product Selection

Publisher Website
Google Scholar
Abstract
The Rationale for Slow-Release TheophyllineIn 1974 a report of a placebo-controlled double-blind crossover study indicated that treatment with theophylline was associated with a dramatic decrease in symptoms and signs of chronic asthma without adverse effects when used in individualized doses that maintained serum theophylline concentrations between 10 and 20 μg per milliliter; doses of theophylline that approximated previous customary usage produced lower serum concentrations and were not effective in reducing symptoms.1 Although some bronchodilatory effect occurs at lower serum concentrations of theophylline,2 these and other data3 suggest that stabilization of the hyperreactive airways that characterize asthma becomes most prominent . . .